Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070902 | 0.95 | KDM4E (0.51) | KDM4EALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL10838932 | 0.73 | CYP1A2 (0.43) | KDM4EALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL10020194 | 0.68 | AOC3 (0.51) | KDM4EALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL10216413 | 0.68 | MAPT (0.44) | KDM4EALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL12432433 | 0.66 | KDM4E (0.47) | KDM4EALDH1A1ADORA2ALMNAHPGD | |
| SCHEMBL12432432 | 0.66 | KDM4E (0.47) | KDM4EALDH1A1ADORA2ALMNAHPGD | |
| SCHEMBL12432437 | 0.66 | KDM4E (0.47) | KDM4EALDH1A1ADORA2ALMNAHPGD | |
| SCHEMBL1861019 | 0.66 | MAPT (0.43) | KDM4EALDH1A1MAPTCYP1A2CYP2C9 | |
| SCHEMBL5238889 | 0.65 | KDM4E (0.44) | KDM4EALDH1A1HPGDHSD17B10TYR | |
| SCHEMBL2515838 | 0.64 | TYMP (0.44) | KDM4EALDH1A1GPR84HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | claimed |
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2006-07-27 | — | — | US | claimed |
| EP-1539780-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | Alchemia Limited (AU) | 2005-06-15 | — | — | EP | claimed |
| WO-2004014929-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | ALCHEMIA LIMITED (AU) | 2004-02-19 | — | — | WO | claimed |
| US-9709571-B2 | Method of drug design | VAST BIOSCIENCE PTY LIMITED (AU) | 2017-07-18 | — | — | US | disclosed |
| US-20130172210-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LIMITED (AU) | 2013-07-04 | — | — | US | disclosed |
| US-8426345-B2 | Method of drug design | ALCHEMIA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2545923-A1 | Antibacterial agents | Alchemia Limited (AU) | 2013-01-16 | — | — | EP | disclosed |
| EP-1934388-B1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2012-12-05 | — | — | EP | disclosed |
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20110165700-A1 | CLASSES OF COMPOUNDS THAT INTERACT WITH INTEGRINS | ALCHEMIA LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| WO-2007070947-A1 | ANTIBACTERIAL AGENTS | ALCHEMIA LTD (AU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1797428-A1 | SELECTIVE INHIBITORS | Alchemia Pty Ltd (AU) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007038829-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006081616-A1 | CLASSES OF COMPOUNDS THAT INTERACT WITH INTEGRINS | ALCHEMIA LIMITED (AU) | 2006-08-10 | — | — | WO | disclosed |
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| WO-2006037159-A1 | SELECTIVE INHIBITORS | ALCHEMIA LIMITED (AU) | 2006-04-13 | — | — | WO | disclosed |
| EP-1539780-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | Alchemia Limited (AU) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014929-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | ALCHEMIA LIMITED (AU) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | FBP1, UGGT1, FUT6 | KDM4E 3797/4885ALDH1A1 554/4885MAPT 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.